Fig. 2From: Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year resultsTime course of infusion-associated reactions (IARs) during olipudase alfa treatmentBack to article page